concentrations, MCP-1, sclerostin, klotho, 25-OH vitamin D were determined using standard methods. RESULTS: CAVI level was 8.2260.18 m/sec in diabetic CKD patients and significantly higher than non-diabetic CKD (7.6160.18 m/sec) and controls (7.5960.17 m/sec). FGF-23 level was higher in CKD groups than controls, but not statistically significant. MCP-1 level was significantly higher in diabetic CKD patients. Klotho and sclerostin levels were signicantly lower in diabetic CKD patients. In CKD patients, CAVI showed positive correlations with age (r¼0.447 p<0.0001), cigarette smoking (r¼0.331, p¼0.035), mean arterial pressure (r¼0.327, p<0.0001), fasting blood glucose (r¼0.185, p¼0.033), HbA1c (r¼0.258, p¼ 0.003). Stepwise regression analysis revealed that age (p¼0.0001, B¼0.461), mean arterial blood pressure ( p<0.0001, B¼0.365), HbA1c (p¼0.003, B¼0.251) and MCP-1 (p¼0.013, B¼0.214) independently predicted CAVI levels. CONCLUSIONS: Our results indicate higher CAVI levels, therefore increased arterial stiffness in the setting of diabetic CKD. Apart from age and mean arterial blood pressure, deranged metabolic status, especially increased HBA1c and MCP-1 levels are also independently associated with increasing CAVI levels in CKD patients. These results emphasize the importance of metabolic control in the development of arterial stiffness in CKD patients, which is an early predictor of developing cardiovascular complications. 
INTRODUCTION AND AIMS:
Chronic kidney disease is a growing challenge in developing countries, particularly in sub-Saharan Africa. There is dearth of information on the epidemiology of CKD in Nigeria that is necessary to estimate its burden in a bid to design preventive and management strategies. The aim of the study is to determine the prevalence of CKD and its risk factors in Kwara State, located in North Central zone of Nigeria. METHODS: Eight communities from 7 local government areas in Kwara State, Nigeria were screened during world kidney days). Blood pressure, fasting and random blood sugar, urinalysis, weight, height, waist circumference (WC) and hip circumference were measured. Body mass index (BMI) and Waist-Hip ratio (WHR) were calculated. Albuminuria, and kidney length by ultrasound were measured in subset of participants while eGFR was derived from serum creatinine, using MDRD formula. formula. RESULTS: A total of 1350 adults, 18years with mean age of 43.70614.12 years were screened, Males accounted for 43% and M: F ratio was 0.75:1. The mean kidney lengths were: right, 93.0268.03cm and left, 92.7069.30cm. The prevalence of proteinuria was 13.5%; hypertension 20.7%; diabetes 2.4%; obesity by BMI was 21% and abdominal obesity by waist circumference was 14.3%. Albuminuria of above 30mg/L was detected in 46.3%, and above 50mg/L in 21.9%. The prevalence of CKD by estimated GFR below 60ml/min/1.73m 2 and/or Proteinuria was 15.8%. Hypertension (OR 1.560, 95%CI ¼ 1.291-1.864, P ¼ 0.006) obesity (OR 1.382, 95%CI ¼ 1.141-1.953, P ¼ 0.008), and age (OR 1.206, 95%CI ¼ 1.07-3.791, P ¼ 0.028) were the identified predictors of CKD. CONCLUSIONS: The prevalence of CKD is high among Nigerians, with hypertension, obesity and advancing age as main risk factors. Efforts should be intensified at preventing and controlling hypertension and obesity in order to reduce the increasing burden of CKD in Nigeria. 
Pulmonary hypertension (PH), a pathological condition defined by increased pulmonary arterial pressure 25 mmHg at rest, is nowadays considered a new, emerging risk factor for mortality and adverse cardiovascular outcomes at the community level. In individuals with heart disease, PH is a powerful predictor of mortality and worsen cardiovascular outcomes independently of age, presence of chronic lung disease and severe heart dysfunction. As sparse evidence exists indicating that PH is highly pervasive also in renal patients, we aimed at performing a systematic review of the available literature to assess :1) the pooled prevalence of PH in CKD and ESKD populations 2) the prognostic impact of this condition on all-cause and cardiovascular mortality and non-fatal cardiovascular events . METHODS: We searched for longitudinal cohort studies dealing with individuals affected by CKD of any-stage (also including ESKD and kidney transplantation) stratified according to presence/absence of PH and with available outcome data on all-cause and cardiovascular mortality and non-fatal cardiovascular events. A random-effects meta-analysis approach was adopted for assessing a pooled PH prevalence and for performing cumulative outcome analyses. Heterogeneity was explored by subgroup or meta-regression analyses. RESULTS: From a source of 5712 potential articles, 18 eligible studies (10740 participants) were retrieved. PH had an overall pooled prevalence (PP) of 0.33 (95% CI 0.28-0.42) that resulted apparently lower in CKD (0.30; 0.13-0.47) than in ESKD (0.35; 0.28-0.42) (Figure 1) . Overall, PH portended a higher risk of all-cause mortality (12 studies, 6638 participants; RR 2.09 ; 95%CI 1.07-4.01), a finding that persisted in ESKD (RR 1.90; 1.61-2.25) while was not confirmed in CKD studies. PH predicted high cardiovascular mortality (3 studies; 1364 participants; RR 3.77; 2.46-5.78) and non-fatal cardiovascular events (9 studies; 7360 participants; RR 1.59; 1.28-1.98), particularly in CKD (RR 1.90; 1.49-2.42). CKD severity, follow-up length and study sample size were the main effect modifiers to the pooled analyses. CONCLUSIONS: PH is a highly prevalent condition in CKD and appears to be a significant risk factor for mortality and worsen cardiovascular outcomes, particularly in selected sub-categories. Future research is advocated to confirm the need for clinical attention on PH and to define benefits of appropriate therapeutic approaches also in the CKD setting 
Albuminuria is a powerful predictor of adverse outcomes in persons with chronic kidney disease (CKD) such that even small increases are associated with substantial additional risk. Regular monitoring for albuminuria is therefore recommended but has proven difficult to achieve, possibly due to uncertainty about benefit. Little is known about the pattern of progression of albuminuria over time in early stage CKD. We therefore sought to investigate the progression of albuminuria over 5 years in a large cohort of persons with CKD stage 3 recruited from primary care practices, where most such patients are managed in the UK. METHODS: Participants with estimated GFR 59-30mL/min/1.73m 2 were prospectively recruited from primary care practices and comprehensively assessed at baseline, year 1 and 5. Albuminuria was assessed at each study visit as the average albumin to creatinine ratio (UACR) on three consecutive early morning urine specimens. 
